Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA12 | O43570 | 8/20 | 0.40 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20880909 | 0.89 | TDP1 (0.38) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL755597 | 0.85 | CA1 (0.40) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL1859283 | 0.85 | EPHX1 (0.43) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL7527615 | 0.84 | EPHX1 (0.46) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL15341460 | 0.84 | EPHX1 (0.46) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL5493650 | 0.84 | TDP1 (0.59) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL11496116 | 0.84 | CA1 (0.39) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL5498803 | 0.84 | TDP1 (0.42) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL16140623 | 0.83 | TDP1 (0.53) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL1865098 | 0.83 | CTSK (0.42) | CA1CA2CA12CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | NOVO NORDISK A/S (DK) | 2010-02-11 | — | — | US | disclosed |
| EP-2086588-A2 | N-TERMINAL PEGYLATED PROLACTIN RECEPTOR MOLECULES | NOVO NORDISK A/S (DK) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008055972-A2 | N-TERMINAL PEGYLATED PROLACTIN RECEPTOR MOLECULES | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | PRLHR, GHRHR, TRHR | CA1 4864/4885CA2 4882/4885CA12 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.